

Nearly half of patients with acute myocardial infarction, including ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), have multivessel disease with significant stenoses in non-culprit vessels, and these patients showed higher risks of death or re-infarction after primary percutaneous coronary intervention (PCI).1 There have been three clinical questions in the treatment of patients with acute myocardial infarction and multivessel disease.
General Medicine
|15th Jan, 2026
|The Lancet
General Medicine
|15th Jan, 2026
|The Lancet
General Medicine
|15th Jan, 2026
|The Lancet
General Medicine
|15th Jan, 2026
|The Lancet
General Medicine
|15th Jan, 2026
|The Lancet
General Medicine
|15th Jan, 2026
|The Lancet
General Medicine
|15th Jan, 2026
|The Lancet